tbuckley/cabot-search huggingface dataset:
Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)
Authors: B. Halmos, G.M. Frampton, J. Suh, E. Braun, R. Mehra, S. Buck, J.A. Bufill, N. Peled, N.A. Karim, P. Fishkin, J. Knost, S.-H.I. Ou, J.S. Ross, P.J. Stephens, V.A. Miller, S.M. Ali, A.B. Schrock
Journal: Annals of Oncology (2016)
Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&amp;MPNr-EuroNet Study,
Authors: Naomi A. Porret, Elisabeth Oppliger Leibundgut, Serge Carillo, Bruno Cassinat, Francois Girodon, Éric Lippert, Valérie Ugo, Sylvie Hermouet, Paola Guglielmelli, Jiri Schwarz, Beatriz Bellosillo, Susanne Schnittger, Maj K. Westman, Stephane Giraudier
Journal: Blood (2011)
Antiemetic prophylaxis (AP) in our clinical practice: are we doing it right?
Authors: E. Vasile, A. Sbrana, G. Musettini, A. Farnesi, I.M. Brunetti, E. Biasco, L. Galli, A. Falcone, S. Ricci, A. Antonuzzo
Journal: Annals of Oncology (2016)
Zeb2-Defficiency in the Adult Murine Hematopoietic Precursor Cells Leads to Differentiation Defects in Multiple Hematopoietic Lineages and a Myeloproliferative-Like Phenotype
Authors: Tamara Riedt, Steven Goossens, Ines Gütgemann, Carmen Carrillo-Garcia, Hichem D Gallala, Holger Fröhlich, Peter Brossart, Dany Huylebroeck, Jody J Haigh, Viktor Janzen
Journal: Blood (2012)
Cardiotoxicity of trastuzumab in the patients with HER2 positive advanced gastric cancer
Authors: M. Jung, J.S. Park, C.-K. Lee, J.H. Kim, H.S. Park, S.J. Heo, S.H. Beom, H.S. Kim, S.Y. Rha, H.C. Chung, J.-C. Youn
Journal: Annals of Oncology (2016)
CHEMICAL STUDIES ON HOST-VIRUS INTERACTIONS
Authors: Seymour S. Cohen, Catherine B. Fowler
Journal: The Journal of Experimental Medicine (1947)

The inhibition of virus multiplication by 5-methyl tryptophane can be specifically reversed by tryptophane. The conditions of reversal indicate that 5MT specifically interferes with tryptophane utilization. The tryptophane requirements of virus multiplication appear to exist throughout the latent period and determine the time of lysis and amount of virus liberated. A latent period may be interrupted for 15 minutes or more and be resumed on addition of tryptophane. Extended inhibition with 5MT results in a somewhat variable "killing" effect, the extent of which determines aspects of the reversal of the inhibition by tryptophane. The implications of these phenomena have been discussed.
A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease
Authors: Martino Introna, Elisa Gotti, Michela Bonzi, Josee Golay, Alessandra Algarotti, Caterina Micò, Anna Grassi, Cristina Boschini, Maria Luisa Ferrari, Irene Cavattoni, Ettore Biagi, Adriana Balduzzi, Attilio Rovelli, Paolo Perseghin, Giuseppe Gaipa, Andrea Biondi, Alessandro Rambaldi
Journal: Blood (2015)
Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
Authors: N.M. Iyengar, L. Smyth, D. Lake, A. Gucalp, J. Singh, T.A. Traina, P. Defusco, M.N. Dickler, M. Fornier, S. Goldfarb, K. Jhaveri, A. Latif, S. Modi, T. Troso-Sandoval, G. Ulaner, M. Jochelson, J. Baselga, L. Norton, C. Hudis, C. Dang
Journal: Annals of Oncology (2016)
Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project
Authors: Flora Peyvandi, Marzia Menegatti, Roberta Palla, Simona Maria Siboni, Marco Boscarino, Halimeh Susan, Munira Borhany, Fatima Naveena, Helen Pergantou, Helen Platokouki, Monique van Meegeren, Paul Brons, Britta Laros-van Gorkom, Meadow Heiman, Amy D Shapiro, Christoph Bidlingmaier, Alessandro Casini, Marko Saracevic, Mikovic Danijela, Nihal Ozdemir, Andrew D Mumford, Hsu Fraustina, John C. Chapin, Andrew Harvey, Majid Naderi, Muriel Giansily, Jean-Francois Schved, Philippe de Moerloose
Journal: Blood (2014)
In Vitro Generation of Mature T Lymphocytes From Human Ips Cells and Genetic Analysis of TCR Gene Rearrangements
Authors: Toshinobu Nishimura, Shin Kaneko, Yoko Tajima, Naoya Takayama, Ai Tachikawa-Kawana, Koji Eto, Hiromitsu Nakauchi
Journal: Blood (2011)
Cancer prevention among residents: Practice and patterns.
Authors: G. O. Akogbe, N. Anumenechi, C. A. Ezigbo
Journal: Journal of Clinical Oncology (2011)

33 Background: At least a third of all cancer cases are preventable. Prevention offers the most cost-effective long- term strategy for the control of cancer; especially in resource deprived areas of the world. Tobacco is the single largest preventable cause of cancer in the world today. Dietary modification is another important approach to cancer control. Infectious agents are responsible for almost 22% of cancer death in the developing world and 6% in industrialized countries. This number is on the rise as result of HIV/AIDS pandemic, life style change and malnutrition. Residents constitute a very important arm of specialized cares in tertiary health institutions. They are the “gate-keepers” who are often the first to come in contact with patients that will benefit from cancer preventive measures. The purpose of this study is therefore, to examine the awareness, attitude and practice of cancer prevention by residents. Methods: Randomly selected residents from the major clinical oncology departments answered questionnaire that addressed these cancer prevention domains; awareness of behavioral modification and early screening, discussing cancer prevention with patients, and participating in screening for common cancer risk factors. Results: 77 out 100 questionnaire distributed were completed and returned; 77% response rate. 97% of the respondents are aware of cancer preventive measures but only 73% of these discussed the measures with patients. 9% of the respondents do not advise patient to quit smoking/not to smoke, only 22% advocate protection against sun, 23% do not advocate for early screening, and only 25% of the respondents themselves are screened for any of the common cancer risk factors while 74% are not. Conclusions: There is significant awareness of cancer prevention measures but not all put this knowledge to practice. Only a quarter of the respondents are themselves screened. Further studies are needed to determine interventions that can improve resident's attitude to cancer prevention in resource deprived economy with rising prevalence of cancer. With improved training opportunities for cancer control among professionals, more cancers will be diagnosed via early screening and detection. No significant financial relationships to disclose.
Development and Analysis of Novel Intravascular Large B-Cell Lymphoma NOD/Shi-Scid IL2Rγnull Mouse Xenograft Model
Authors: Kazuyuki Shimada, Satoko Shimada, Keiki Sugimoto, Fumihiko Hayakawa, Miyuki Katayama, Akihiro Hirakawa, Yusuke Takagi, Shigeo Nakamura, Masao Seto, Tomoki Naoe, Akihiro Tomita, Hitoshi Kiyoi
Journal: Blood (2014)
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
Authors: A. Zick, T. Peretz, M. Lotem, A. Hubert, D. Katz, M. Temper, Y. Rottenberg, B. Uziely, H. Nechushtan, A. Meirovitz, A. Sonnenblick, E. Sapir, D. Edelman, Y. Goldberg, A. Lossos, S. Rosenberg, I. Fried, R. Finklstein, E. Pikarsky, H. Goldshmidt
Journal: Annals of Oncology (2016)
EXTH-02. PRETREATMENT OF MESENCHYMAL STEM CELLS CARRYING CYTOSINE DEAMINASE GENE ENHANCES THE THERAPEUTIC EFFECTS OF TMZ IN ORTHOTOPIC GLIOMA MODEL
Authors: Jin-Hwa Jung, Da-Young Chang, Andrew Aujin Kim, Young-Don Lee, Haeyoung Suh-Kim, Sung-Soo Kim
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, and the current standard therapy provides modest improvement in the progression-free and overall survival of patients. The innate resistance and invasiveness of the tumor and the presence of the blood-brain barrier (BBB) require the development of multi-modal therapeutic regimens. Previously, we demonstrated that cytosine deaminase (CD)-expressing mesenchymal stem cells (MSC/CD) exerted an anticancer activity with a minimized therapeutic index by converting 5-fluorocytosine (5-FC), a nontoxic prodrug, into 5-fluorouracil (5-FU), a potent anticancer drug. In this study, we evaluated a potential use of MSC/CD in a multi-modal regimen in combination with temozolomide (TMZ), which is one of the most commonly used drugs for treating GBM. TMZ and MSC/CD with 5-FC synergistically interacted and suppressed the growth of U87 glioma cell line in vitro. Combined treatment with TMZ and 5-FU, a metabolite of MSC/CD and 5-FC, increased cell cycle arrest and DNA breakage. In an orthotopic xenograft mouse model, treatment with TMZ alone suppressed the growth of tumor mass; however, this effect was more intense with the MSC/CD transplantation followed by the sequential treatment 5-FC and TMZ. Therefore, we propose that sequential treatment with 5-FC and MSC/CD can be used to treat patients with GBM during the immediate postoperative period to sensitize the tumor to subsequent adjuvant chemo- and radiotherapy.
An Etiquette-Based Medicine Decalogue on the Professional style in the Multidisciplinary Unit (UVM) of Cosenza Hospital Oncology Department
Authors: A. Piattelli, R. Biamonte, S. Turano, C. Manfredi, C.M. Mastroianni, R. De Simone, S. Minardi, M. Bartucci, L. Marafioti, S. Conforti, A. Filice, V. Liguori, M. Loizzo, A. Rovito, M.D. Iuvaro, A. Toretti, E. Colistra, S. Palazzo
Journal: Annals of Oncology (2016)
D-Dimer in the Months Leading up to Acute Coronary Events: A Case Crossover Study
Authors: David Green, Yihua Liao, Loyda Vida, Philip Greenland, Mark D Huffman, Kiang J Liu, Donald M Lloyd-Jones, Sanjiv J Shah, Lu Tian, Russell P Tracy, John T Wilkins, Lihui Zhao, Mary M McDermott
Journal: Blood (2014)
TMOD-37. CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES
Authors: Mohini Singh, Chitra Venugopal, Tomas Tokar, Nicole McFarlane, David Bakhshinyan, Naresh Murty, John Hassell, Igor Jurisica, Sheila Singh
Journal: Neuro-Oncology (2016)

Brain Metastases (BM) are the most common neoplasm to affect the adult central nervous system, occurring at a rate 10 times greater than that of primary brain cancers. Despite the prevalence and severe lethality of BM, the current available in vivo models of metastasis neither fully recapitulate the clinical progression of BM nor allow for proper examination of metastatic cells. Not every cell within a primary tumour possess the ability to survive metastasis, and studies typical investigate large macro-metastases formed by cells that have already exited the metastatic cycle. We hypothesize that within primary tumours exists a subpopulation of CSC-like cells, termed brain metastasis-initiating cells (BMICs), which are responsible for initiating BMs. We have recently generated a novel patient-derived xenotransplantation (PDX) model of BM that allows for interrogation of each phase of the metastatic process from lung to brain, through injection of human patient-derived BMICs into immunocompromised mice. We then expanded our model to incorporate BMs from breast and melanoma primaries. BMICs were harvested from primary sites and corresponding BMs, and RNA submitted for sequencing to identify a metastatic and tissue-specific gene signatures. From our novel PDX model we were able to interrogate micro-metastasis formation, where we found BMICs to possess a unique genomic profile as compared to BMICs isolated from full primary tumors and complete macro-metastases. These BMICs exhibit increased expression of stem cell, epithelial-to-mesenchymal transition, and quiescence genes. Through in silico analysis we generated a preliminary list of therapeutics targeting these unique BMICs. Future work will identify novel therapeutics that block the metastatic process by targeting these unique BMICs, and assess the clinical utility of this novel BMIC signature in predicting BMs of different origins. Ultimately we aim to transform a uniformly fatal systemic disease into a locally controlled and eminently more treatable one.
Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases
Authors: Kyunghee Byun, YongCheol Yoo, Myeongjoo Son, Jaesuk Lee, Goo-Bo Jeong, Young Mok Park, Ghasem Hosseini Salekdeh, Bonghee Lee
Journal: Pharmacology & Therapeutics (2017)

Advanced glycation end products (AGEs) and their receptor have been implicated in the progressions of many intractable diseases, such as diabetes and atherosclerosis, and are also critical for pathologic changes in chronic degenerative diseases, such as Alzheimer's disease, Parkinson's disease, and alcoholic brain damage. Recently activated macrophages were found to be a source of AGEs, and the most abundant form of AGEs, AGE-albumin excreted by macrophages has been implicated in these diseases and to act through common pathways. AGEs inhibition has been shown to prevent the pathogenesis of AGEs-related diseases in human, and therapeutic advances have resulted in several agents that prevent their adverse effects. Recently, anti-inflammatory molecules that inhibit AGEs have been shown to be good candidates for ameliorating diabetic complications as well as degenerative diseases. This review was undertaken to present, discuss, and clarify current understanding regarding AGEs formation in association with macrophages, different diseases, therapeutic and diagnostic strategy and links with RAGE inhibition.
Diagnostic value of methylation status of T-UCRs for colorectal cancer
Authors: A. Kottorou, A. Antonacopoulou, F.-I. Dimitrakopoulos, G. Diamantopoulou, T. Theodorakopoulos, C. Oikonomou, I. Koukourikou, D. Dalla, P. Karatasou, E. Katsakoulis, A. Koutras, T. Makatsoris, M. Stavropoulos, K. Thomopoulos, H. Kalofonos
Journal: Annals of Oncology (2016)
CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.
Authors: Matthew A Lunning, April Chiu, Julie Teruya Feldstein, Jocelyn C. Maragulia, Alison Moskowitz, Matthew J. Matasar, David J. Straus, Ariela Noy, Patricia L Myskowski, Andrew D. Zelenetz, Steven M. Horwitz
Journal: Blood (2012)
Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia
Authors: Pamela S. Becker, Elihu Estey, Stephen Petersdorf, Paul C. Hendrie, John M. Pagel, Derek Stirewalt, Andrei Shustov, Barry E. Storer, Frederick R. Appelbaum
Journal: Blood (2008)
PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas,
Authors: Esperanza Martin-Sanchez, Socorro M. Rodriguez-Pinilla, Luis Lombardia, Beatriz Dominguez-Gonzalez, Margarita Sanchez-Beato, Diana Romero, Magdalena B. Wozniak, Manuela Mollejo, Javier Alves, Jose Luis Rodriguez-Peralto, Javier Menarguez, Juan C. Cigudosa, Pablo L. Ortiz-Romero, Juan F. Garcia, James R. Bischoff, Miguel A. Piris
Journal: Blood (2011)
Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study
Authors: A. Mario Q. Marcondes, Mohamed L. Sorror, Ekapun Karoopongse, Terry Furlong, Marina Lesnikova, Sabina Janciauskiene, Charles A. Dinarello, H. Joachim Deeg
Journal: Blood (2014)
IMST-59. MODULATING GLIOMA-MEDIATED MYELOID-DERIVED SUPPRESSOR CELL DEVELOPMENT WITH SULFORAPHANE
Authors: Ravi Kumar, Tristan de Mooij
Journal: Neuro-Oncology (2016)

Glioblastoma is the most common primary tumor of the brain and has terrible long-term survival. Local and systemic immunosuppressive environment created by glioblastoma allows it to evade immunosurveillance. Myeloid-derived suppressor cells (MDSCs) are a critical component of this immunosuppression. Understanding mechanisms of MDSC formation and function are key to developing effective immunotherapies. A series of in vitro experiments were conducted to generate MDSC’s from healthy donor CD14+ monocytes by culture in glioma-conditioned media from patient-derived cell lines. Flow cytometry and confocal microscopy were used to identify MDSC’s. Glioma-conditioned media was screened by a fluorescent array for immunosuppressive cytokines. Impact of a naturally occurring inhibitor of one of these cytokines on monocyte differentiation to MDSC’s was assessed. Culture in glioma-conditioned media robustly stimulated development of monocytic MDSC’s (CD14+/ HLA-DR-) from healthy monocytes. These MDSC’s inhibited T cell proliferation. Multiple cytokines were identified in glioma-conditioned media that could contribute to MDSC generation, including Monocyte Chemoattractive Protein-1, interleukin-6, interleukin-8, and Macrophage Migration Inhibitory Factor (MIF). Of these, MIF was a particularly attractive therapeutic target as sulforaphane, a naturally occurring MIF inhibitor derived from cruciferous vegetables, has excellent oral bioavailability. Sulforaphane inhibited transformation of normal monocytes to MDSCs by glioma-conditioned media in vitroat pharmacologically relevant concentrations that were non-toxic to normal leukocytes. This was associated with a corresponding increase in mature dendritic cells. Interestingly, sulforaphane treatment had similar pro-inflammatory effects on normal monocytes in fresh media but specifically increased immature dendritic cells unless glioma-conditioned media was present. We used a simple in vitro model system to identify MIF as a novel contributor to glioblastoma immunosuppression. Sulforaphane, a naturally occurring MIF inhibitor, increases mature dendritic cell development at the expense of myeloid-derived suppressor cells when normal monocytes are exposed to glioma-conditioned media.
CREBBP alterations found in extreme responders to PD-1 inhibition in patients (pts) with refractory solid tumors treated in a phase 1 trials unit
Authors: V. Boni, J. Garcia-Donas, E. Garralda, C. Muñoz Sanchez-Miguel, A. Calles, J.F. Rodriguez-Moreno, E. Calvo
Journal: Annals of Oncology (2016)
Phase II-trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell head and neck cancer: 5-year end results
Authors: T. Kuhnt, A. Schreiber, A. Pirnasch, M.G. Hautmann, P. Hass, F.P. Sieker, R. Engenhart-Cabilic, M. Richter, K. Dellas, J. Dunst
Journal: Annals of Oncology (2016)
Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial
Authors: Stephen E Spurgeon, Kamal Sharma, David F. Claxton, Christopher W. Ehmann, Carla Gallagher, Sara Shimko, August Stewart, Samir Parekh, Violetta V. Leshchenko, Yiyi Chen, Elliot M Epner
Journal: Blood (2012)
Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential
Authors: Tomohiro Tamura, Tomonaga Ichikawa, Shingo Nakahata, Yudai Kondo, Yuri Tagawa, Koji Yamamoto, Kentaro Nagai, Takashi Baba, Ryoji Yamaguchi, Mitsuru Futakuchi, Yoshihiro Yamashita, Kazuhiro Morishita
Journal: Cancer Research (2017)

Abstract Loss of the tumor suppressor NDRG2 has been implicated in the development of oral squamous cell carcinoma (OSCC), acting by modulating PI3K/AKT-mediated dephosphorylation of PTEN at S380/S382/T383 (STT). Here, we show that the majority of OSCC tumors with lymph node metastasis, a major prognostic factor, exhibit high levels of phosphorylated AKT-S473 and PTEN-STT and low levels of NDRG2 expression. In Ndrg2-deficient mice, which develop a wide range of tumors, we developed a model of OSCC by treatment with the tobacco surrogate 4-nitroquinoline-1-oxide (4-NQO). In this model, both the number and size of OSCC tumors were increased significantly by Ndrg2 deficiency, which also increased invasion of cervical lymph nodes. 4-NQO treatment of human OSCC cell lines exhibiting low NDRG2 expression induced epithelial–mesenchymal transition via activation of NF-κB signaling. Conversely, ectopic expression of NDRG2 reversed the EMT phenotype and inhibited NF-κB signaling via suppression of PTEN-STT and AKT-S473 phosphorylation. Our results show how NDRG2 expression serves as a critical determinant of the invasive and metastatic capacity of OSCC. Cancer Res; 77(9); 2363–74. ©2017 AACR.
HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Authors: Francesca Lorentino, Fabio Ciceri, Myriam Labopin, Zafer Gülbas, Yener Koc, William Arcese, Benedetto Bruno, Johanna Tischer, Andrea Bacigalupo, Didier Blaise, Giuseppe Messina, Martin Bornhäuser, Katharina Fleischhauer, Dietrich W. Beelen, Annalisa Ruggeri, Arnon Nagler, Mohamad Mohty
Journal: Blood (2015)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience
Authors: B. T. J. Hennessy, H. Kuerer, A. Sahin, A. U. Buzdar, S. W. Kau, S. E. Singletary, G. N. Hortobagyi, V. Valero
Journal: Journal of Clinical Oncology (2004)

604 Background: Following primary chemotherapy (PCT) for cytologically confirmed axillary node-positive (LN+) breast cancer (BC), patients (pts) who undergo conversion to negative axillary lymph nodes (LN neg) on hematoxylin & eosin (H&E) examination subsequently have a 5-year disease-free survival (DFS) rate of 87% (median follow-up of 61 months), whereas those with residual nodal disease after PCT have a 5-year DFS rate of 51% (Kuerer et al, JCO 1999). We present the 10-year outcome of the 43 pts in this review who achieved a pathologically complete axillary response with PCT, as well as another 26 pts treated subsequent to the publication of this data who also achieved complete axillary conversion with primary chemotherapy. Methods: Pts with cytologically documented axillary lymph node metastases were treated in four prospective trials of doxorubicin- or taxane-based PCT and were identified following subsequent definitive surgery to have complete histologic eradication of lymph node disease by H&E. Survival was calculated by the Kaplan-Meier method. Results: Fifty-two percent (n=36) of the pts had N1 disease, and 46% (n=32) had N2 disease. The majority of tumors were ductal (97%). In 60 cases, the estrogen receptor (ER) status was known. Of these, 75% were ER negative. The median follow-up was 73 months (range, 18–169 months). The relapse-free survival (RFS) rate of the group was 89% at 5 and 10 years. Overall survival (OS) rate was 92% at 5 years and 84% at 10 years. Forty-two patients (61%) had histologic eradication of disease in the breast in addition to the axillary nodal basin. For this group, RFS was 90% at 5 and 10 years, and OS was 93% at 5 years and 85% at 10 years, very similar to the outcome of patients who had residual disease in the breast (but not axilla) after neoadjuvant treatment (RFS 89% at 5 and 10 years, and OS 90% at 5 years and 83% at 10 years). Conclusions: Patients with complete histologic eradication of axillary metastatic disease by PCT have an excellent long-term DFS and OS. No significant financial relationships to disclose.
Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder
Authors: Sei-ichiro Yoshizawa, Junko H Ohyashiki, Michiyo Ohyashiki, Tomohiro Umezu, Kenshi Suzuki, Atsushi Inagaki, Shinsuke Iida, Kazuma Ohyashiki
Journal: Blood (2011)
The Association of KIR2DS4 and Its Variant KIR1D with CMV Infection after HLA-Matched Sibling Hematopoietic Stem Cell Transplantation
Authors: Yao Yao, Xiaoli Li, Liangjing Xu, Bin Liu, Yue Han, Xiaopeng Tian, Chengcheng Fu, Xiaojing Bao, Jun He, Xiaojin Wu, Wu Depei
Journal: Blood (2014)